RadMD new headquarters
RadMD, celebrated a significant milestone as we commemorated the opening of our new office in Conshohocken, PA last week. The achievement marks a remarkable journey that began 17 years ago in a barn located in rural Pennsylvania. As RadMD moves…
The American Society of Clinical Oncology (ASCO) Conference
The American Society of Clinical Oncology (ASCO) Conference took place from June 2nd to June 6th, 2023, and RadMD was among the attendees. During the conference, RadMD provided an opportunity for professionals involved in planning early phase…
Clinical Operations in Oncology Trials West Coast
RadMD Co-Founder and Principal, Kohkan Shamsi, attended the Clinical Operations in Oncology Trials West Coast this week. During the event, Shamsi presented a session titled 'early phase oncology imaging endpoints: optimizing the opportunity and…
RadMD welcomes Rendon Nelson to the team
RadMD would like to extend a warm welcome to Rendon Nelson, MD, who has joined us as Director of medical and scientific affairs. Rendon was a tenured Professor of Radiology at Duke University, serving in numerous administrative roles including the…
BICR Reader Training Practices that enable Best Performance
You are invited to an interactive RadMD Webinar - BICR Reader Training Practices to ensure Best Performance Presenter: Dr. Rick Patt, RadMD Co-founder and Panelist: Dr. Rendon Nelson, RadMD Medical Director During this webinar, members of…
Co-Founder Dr Kohkan Shamsi confirmed as RSNA 2022 speaker
Dr Kohkan Shamsi, RadMD co-founder, has been confirmed as a speaker for RSNA 2022 Dr Shamsi is booked to discuss “The Effect of Food Intake on Pharmacodynamics of A Novel Oral Liver-specific Contrast Agent: Orviglance (Manganese Chloride…
Clinical Evidence Supports Dotarem® Injection for MR Imaging
New Article in Applied Radiology, the Journal of Practical Medical Imaging and Management: Magnetic resonance imaging (MRI) contrast agents are widely used to increase the contrast difference between normal and abnormal tissues. Also known as…
RadMD managed imaging for a phase II trial for Ipsen biopharmaceuticals’ new Gallium PET imaging agent
RadMD managed imaging for a phase II trial for Ipsen biopharmaceuticals’ new Gallium PET imaging agent to assess somatostatin receptor (SSTR2) positive gastroenteropancreatic neuroendocrine tumor (GEP-NET) that employed novel independent read…
Kohkan Shamsi, in collaboration with ICPME, develops an accredited course
Kohkan Shamsi, in collaboration with ICPME, develops an accredited course intended to educate on the potential implications of ordering and performing contrast-enhanced MRIs The use of gadolinium-based contrast agents in MR imaging has been…
Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer’s disease:
A randomized, controlled, double-blind, parallel-arm, phase 3 trial. Leuco-methylthioninium bis(hydromethanesulfonate; LMTM), a stable reduced form of the methylthioninium moiety, acts as a selective inhibitor of tau protein aggregation both in…